Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)

October 9, 2026 7:05 AM EDT Send to a Friend
Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst commented: "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login